Trial Profile
Prospective, double-blind, multicenter, placebo-controlled study investigating effectiveness of atomoxetine in young adults with Attention Deficit Hyperactivity Disorder (ADHD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2015
Price :
$35
*
At a glance
- Drugs Atomoxetine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Biomarker; Diagnostic use; Pharmacodynamics
- 04 Nov 2015 New trial record